Peter Spaeth

Peter Spaeth

WilmerHale

Contact
View Bio
RSS

Latest Posts › Antitrust Provisions

Share:

FDA Publishes List of Drug Companies Accused of Hindering Generic Entry: Antitrust Implications

Today, as part of the Trump Administration's stated goal to lower drug prices, the Food and Drug Administration (FDA) published a list of pharmaceutical companies that have allegedly refused to sell samples of their drugs to...more

5/18/2018  /  Abbreviated New Drug Application (ANDA) , Antitrust Provisions , Department of Health and Human Services (HHS) , Food and Drug Administration (FDA) , Generic Drugs , Hatch-Waxman , Pharmaceutical Industry , REMS , Sherman Act , The Clayton Act

District Court Rejects Direct Purchaser Class for Failure to Satisfy Numerosity Requirement

On August 28, 2017, in King Drug Company of Florence, Inc., et al. v. Cephalon, Inc., et al., the Eastern District of Pennsylvania denied class certification for direct purchasers asserting Hatch-Waxman reverse-payment...more

8/31/2017  /  Antitrust Litigation , Antitrust Provisions , Direct Purchasers , Hatch-Waxman , Pharmaceutical Industry , Putative Class Actions , Remand , Retailers , Reverse Payment Settlement Agreements , Reverse Payments
2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide